Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(8):552-553; doi:10.1093/jnci/97.8.552
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vanchieri, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vanchieri, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Researchers Plan To Continue To Study COX-2 Inhibitors in Cancer Treatment and Prevention

Cori Vanchieri

The first 150 words of the full text of this article appear below.

Several cyclooxygenase 2 (COX-2) inhibitors have taken a beating from recent evidence that they can cause deaths from heart attack and stroke, but some cancer researchers say that the drugs are too promising as possible chemoprevention agents to abandon them completely.

Rofecoxib (Vioxx) was withdrawn from the market in September when a colon cancer chemoprevention trial revealed an increased risk of heart attacks and strokes among long-term users (see News, Vol. 96, No. 23, p. 1734, "Vioxx Withdrawal Alarms Cancer Prevention Researchers"). Soon after, valdecoxib (Bextra) was shown to increase heart attacks in people who recently had coronary artery bypass surgery.

Bad news for celecoxib (Celebrex), the COX-2 inhibitor used most frequently in prevention trials, came in December: It also increased the risk of heart attacks in a cancer prevention trial. Drug administration was stopped on dozens of cancer prevention trials, other studies were halted, and a U.S. . . . [Full Text of this Article]

Does it Work in Cancer?

Which Cohorts Are Worth Pursuing?

NSAIDs and COX-2 Inhibitors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
D.-M. Hwang, J. K. Kundu, J.-W. Shin, J.-C. Lee, H. J. Lee, and Y.-J. Surh
cis-9,trans-11-Conjugated linoleic acid down-regulates phorbol ester-induced NF-{kappa}B activation and subsequent COX-2 expression in hairless mouse skin by targeting I{kappa}B kinase and PI3K-Akt
Carcinogenesis, February 1, 2007; 28(2): 363 - 371.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. K. Kundu, Y. K. Shin, S. H. Kim, and Y.-J. Surh
Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-{kappa}B in mouse skin by blocking I{kappa}B kinase activity
Carcinogenesis, July 1, 2006; 27(7): 1465 - 1474.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Kardosh, N. Soriano, Y.-T. Liu, J. Uddin, N. A. Petasis, F. M. Hofman, T. C. Chen, and A. H. Schonthal
Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib
Blood, December 15, 2005; 106(13): 4330 - 4338.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
D. M. Olson
The Promise of Prostaglandins: Have They Fulfilled Their Potential as Therapeutic Targets for the Delay of Preterm Birth?
Reproductive Sciences, October 1, 2005; 12(7): 466 - 478.
[Abstract] [PDF]